Changes in anxiety and depression symptoms associated to the outcome of MOH: A post-hoc analysis of the Comoestas Project

Sara Bottiroli, Marta Allena, Grazia Sances, Roberto De Icco, Micol Avenali, Ricardo Fadic, Zaza Katsarava, Miguel Ja Lainez, Maria Teresa Goicochea, Rigmor Højland Jensen, Giuseppe Nappi, Cristina Tassorelli, Comoestas Consortium

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Aims To evaluate the impact of treatment success on depression and anxiety symptoms in medication-overuse headache (MOH) and whether depression and anxiety can be predictors of treatment outcome. Methods All consecutive patients entering the detoxification program were analysed in a prospective, non-randomised fashion over a six-month period. Depression and anxiety were assessed using the Hospital Anxiety and Depression Scale. Results A total of 663 MOH patients were evaluated, and 492 completed the entire protocol. Of these, 287 ceased overuse and reverted to an episodic pattern (responders) and 23 relapsed into overuse. At the final evaluation, the number of patients with depressive symptoms was reduced by 63.2% among responders ( p < 0.001) and did not change in relapsers ( p = 0.13). Anxious symptomatology was reduced by 43.1% in responders ( ps < 0.001) and did not change in relapsers ( p = 0.69). At the multivariate analysis, intake of a prophylactic drug and absence of symptoms of depression at six months emerged as prognostic factors for being a responder (OR 2.406; p = 0.002 and OR 1.989; p = 0.019 respectively), while lack of antidepressant drugs and presence of symptoms of depression at six months were prognostic factors for relapse into overuse (OR 3.745; p = 0.004 and OR 3.439; p = 0.031 respectively). Conclusions Symptomatology referred to affective state and anxiety can be significantly reduced by the treatment of MOH. Baseline levels of depression and anxiety do not generally predict the outcome at six months. Their persistence may represent a trait of patients with a negative outcome, rather than the consequence of a treatment failure.

Original languageEnglish
Pages (from-to)333102417704415
JournalCephalalgia
DOIs
Publication statusE-pub ahead of print - Jan 1 2017

Fingerprint

Secondary Headache Disorders
Anxiety
Depression
Treatment Failure
Antidepressive Agents
Multivariate Analysis

Keywords

  • Journal Article

Cite this

Changes in anxiety and depression symptoms associated to the outcome of MOH : A post-hoc analysis of the Comoestas Project. / Bottiroli, Sara; Allena, Marta; Sances, Grazia; De Icco, Roberto; Avenali, Micol; Fadic, Ricardo; Katsarava, Zaza; Lainez, Miguel Ja; Goicochea, Maria Teresa; Jensen, Rigmor Højland; Nappi, Giuseppe; Tassorelli, Cristina; Comoestas Consortium.

In: Cephalalgia, 01.01.2017, p. 333102417704415.

Research output: Contribution to journalArticle

Bottiroli, Sara ; Allena, Marta ; Sances, Grazia ; De Icco, Roberto ; Avenali, Micol ; Fadic, Ricardo ; Katsarava, Zaza ; Lainez, Miguel Ja ; Goicochea, Maria Teresa ; Jensen, Rigmor Højland ; Nappi, Giuseppe ; Tassorelli, Cristina ; Comoestas Consortium. / Changes in anxiety and depression symptoms associated to the outcome of MOH : A post-hoc analysis of the Comoestas Project. In: Cephalalgia. 2017 ; pp. 333102417704415.
@article{419307cf04a947d38593fea1dce02cf6,
title = "Changes in anxiety and depression symptoms associated to the outcome of MOH: A post-hoc analysis of the Comoestas Project",
abstract = "Aims To evaluate the impact of treatment success on depression and anxiety symptoms in medication-overuse headache (MOH) and whether depression and anxiety can be predictors of treatment outcome. Methods All consecutive patients entering the detoxification program were analysed in a prospective, non-randomised fashion over a six-month period. Depression and anxiety were assessed using the Hospital Anxiety and Depression Scale. Results A total of 663 MOH patients were evaluated, and 492 completed the entire protocol. Of these, 287 ceased overuse and reverted to an episodic pattern (responders) and 23 relapsed into overuse. At the final evaluation, the number of patients with depressive symptoms was reduced by 63.2{\%} among responders ( p < 0.001) and did not change in relapsers ( p = 0.13). Anxious symptomatology was reduced by 43.1{\%} in responders ( ps < 0.001) and did not change in relapsers ( p = 0.69). At the multivariate analysis, intake of a prophylactic drug and absence of symptoms of depression at six months emerged as prognostic factors for being a responder (OR 2.406; p = 0.002 and OR 1.989; p = 0.019 respectively), while lack of antidepressant drugs and presence of symptoms of depression at six months were prognostic factors for relapse into overuse (OR 3.745; p = 0.004 and OR 3.439; p = 0.031 respectively). Conclusions Symptomatology referred to affective state and anxiety can be significantly reduced by the treatment of MOH. Baseline levels of depression and anxiety do not generally predict the outcome at six months. Their persistence may represent a trait of patients with a negative outcome, rather than the consequence of a treatment failure.",
keywords = "Journal Article",
author = "Sara Bottiroli and Marta Allena and Grazia Sances and {De Icco}, Roberto and Micol Avenali and Ricardo Fadic and Zaza Katsarava and Lainez, {Miguel Ja} and Goicochea, {Maria Teresa} and Jensen, {Rigmor H{\o}jland} and Giuseppe Nappi and Cristina Tassorelli and {Comoestas Consortium}",
year = "2017",
month = "1",
day = "1",
doi = "10.1177/0333102417704415",
language = "English",
pages = "333102417704415",
journal = "Cephalalgia",
issn = "0333-1024",
publisher = "SAGE Publications Ltd",

}

TY - JOUR

T1 - Changes in anxiety and depression symptoms associated to the outcome of MOH

T2 - A post-hoc analysis of the Comoestas Project

AU - Bottiroli, Sara

AU - Allena, Marta

AU - Sances, Grazia

AU - De Icco, Roberto

AU - Avenali, Micol

AU - Fadic, Ricardo

AU - Katsarava, Zaza

AU - Lainez, Miguel Ja

AU - Goicochea, Maria Teresa

AU - Jensen, Rigmor Højland

AU - Nappi, Giuseppe

AU - Tassorelli, Cristina

AU - Comoestas Consortium

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Aims To evaluate the impact of treatment success on depression and anxiety symptoms in medication-overuse headache (MOH) and whether depression and anxiety can be predictors of treatment outcome. Methods All consecutive patients entering the detoxification program were analysed in a prospective, non-randomised fashion over a six-month period. Depression and anxiety were assessed using the Hospital Anxiety and Depression Scale. Results A total of 663 MOH patients were evaluated, and 492 completed the entire protocol. Of these, 287 ceased overuse and reverted to an episodic pattern (responders) and 23 relapsed into overuse. At the final evaluation, the number of patients with depressive symptoms was reduced by 63.2% among responders ( p < 0.001) and did not change in relapsers ( p = 0.13). Anxious symptomatology was reduced by 43.1% in responders ( ps < 0.001) and did not change in relapsers ( p = 0.69). At the multivariate analysis, intake of a prophylactic drug and absence of symptoms of depression at six months emerged as prognostic factors for being a responder (OR 2.406; p = 0.002 and OR 1.989; p = 0.019 respectively), while lack of antidepressant drugs and presence of symptoms of depression at six months were prognostic factors for relapse into overuse (OR 3.745; p = 0.004 and OR 3.439; p = 0.031 respectively). Conclusions Symptomatology referred to affective state and anxiety can be significantly reduced by the treatment of MOH. Baseline levels of depression and anxiety do not generally predict the outcome at six months. Their persistence may represent a trait of patients with a negative outcome, rather than the consequence of a treatment failure.

AB - Aims To evaluate the impact of treatment success on depression and anxiety symptoms in medication-overuse headache (MOH) and whether depression and anxiety can be predictors of treatment outcome. Methods All consecutive patients entering the detoxification program were analysed in a prospective, non-randomised fashion over a six-month period. Depression and anxiety were assessed using the Hospital Anxiety and Depression Scale. Results A total of 663 MOH patients were evaluated, and 492 completed the entire protocol. Of these, 287 ceased overuse and reverted to an episodic pattern (responders) and 23 relapsed into overuse. At the final evaluation, the number of patients with depressive symptoms was reduced by 63.2% among responders ( p < 0.001) and did not change in relapsers ( p = 0.13). Anxious symptomatology was reduced by 43.1% in responders ( ps < 0.001) and did not change in relapsers ( p = 0.69). At the multivariate analysis, intake of a prophylactic drug and absence of symptoms of depression at six months emerged as prognostic factors for being a responder (OR 2.406; p = 0.002 and OR 1.989; p = 0.019 respectively), while lack of antidepressant drugs and presence of symptoms of depression at six months were prognostic factors for relapse into overuse (OR 3.745; p = 0.004 and OR 3.439; p = 0.031 respectively). Conclusions Symptomatology referred to affective state and anxiety can be significantly reduced by the treatment of MOH. Baseline levels of depression and anxiety do not generally predict the outcome at six months. Their persistence may represent a trait of patients with a negative outcome, rather than the consequence of a treatment failure.

KW - Journal Article

U2 - 10.1177/0333102417704415

DO - 10.1177/0333102417704415

M3 - Article

C2 - 28399650

SP - 333102417704415

JO - Cephalalgia

JF - Cephalalgia

SN - 0333-1024

ER -